CSTL Stock Analysis: Buy, Sell, or Hold?
CSTL - Castle Biosciences, Inc. Common Stock
$39.39
0.23 (0.59%)
▲
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
23d
Get Alerted When CSTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CSTL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CSTL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CSTL is currently trading at $39.39, which is considered slightly low relative to its 30-day fair value range of $38.99 to $41.42.
Technical Outlook: Technically, CSTL is in a strong uptrend. Immediate support is located at $38.20, while resistance sits at $44.28.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.57 (+18.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CSTL is in a strong uptrend. Immediate support is located at $38.20, while resistance sits at $44.28.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.57 (+18.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$38.99 -
$41.42
Company Quality Score
41/100
(HOLD)
Options IV Signal
25th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 25th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($46.57)
- CAUTION: Recommendation downgraded due to -6.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$38.99 -
$41.42
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$3.95
(10.0%)
Support & Resistance Levels
Support Level
$38.20
Resistance Level
$44.28
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-34.29
Wall Street Target
$46.57
(+18.2%)
Revenue Growth (YoY)
-3.2%
Earnings Growth (YoY)
-51.6%
Profit Margin
-3.6%
Last updated: February 01, 2026 7:15 PM ET
Data refreshes hourly during market hours. Next update: 8:15 PM
Data refreshes hourly during market hours. Next update: 8:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Derek J Maetzold
SELL
1339 shares
2025-10-20
Derek J Maetzold
SELL
1339 shares
2025-09-17
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$666 | 47 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 57 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$125 | 62 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 47 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$257 | 58 HOLD |
